Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.82 |
| ▸ | NPC1 | O15118 | 6/20 | 0.82 |
| ▸ | RAB9A | P51151 | 6/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.80 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.73 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.71 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.71 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.71 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8353831 | 0.90 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL14202814 | 0.90 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL27022345 | 0.90 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL10576093 | 0.90 | SMN1; SMN2 (0.78) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL9332424 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL15376318 | 0.88 | MAPT (0.78) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL8358016 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL9725030 | 0.85 | NPC1 (0.74) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL17287673 | 0.85 | CSNK1D (1.00) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 | |
| SCHEMBL16299055 | 0.84 | CSNK1D (1.00) | SMN1; SMN2NPC1RAB9AHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368467-B2 | Calcium channel modulators 2-(alkyl or (hetero)arylalkylthio)-imidazoles and S-oxides thereof; angina, hypertension, congestive heart failure, myocardial ischemia, arrhythmia, diabetes, urinary incontinence, stroke, pain, brain injury, or neuronal disorders | WYETH (US) | 2008-05-06 | — | — | US | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | SMN1; SMN2 4558/4885NPC1 6/4885RAB9A 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.